Search clinical trials for: Tetracaine 0.5% ophthalmic drops

Total 905 results

Aldeyra Therapeutics, Inc.

Completed

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis | Seasonal Allergies

Canada
Aldeyra Therapeutics, Inc.
ORA, Inc.

Completed

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Queen's University

Withdrawn

Effect of Tetracaine on Pain Management and Corneal Healing in Patients With Acute Corneal Abrasion

Corneal Abrasion
Minnesota Eye Consultants, P.A.
Bausch & Lomb Incorporated

Completed

The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer

Allergic Conjunctivitis

United States
Allgenesis Biotherapeutics Inc.

Completed

A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia (SURPH)

Pterygium

Australia
Alcon Research

Completed

Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION

Dry Eye
Alcon Research

Completed

Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects

Dry Eye

India
Democritus University of Thrace
George Papanicolaou Hospital; Naval Hospital, Athens; Athinaiki General Clinic

Completed

Impact of 0.1% and 0.2% Sodium Hyaluronate on Postoperative Discomfort Following Phacoemulsification Surgery

Cataract

Greece
Laurantis Pharma, Ltd.
Kuopio University Hospital

Completed

Safety, Tolerability and Pharmacokinetics of 0.5% and 2.5% Cis-UCA Eye Drops in Adult Healthy Volunteers (Phase I)

Dry Eye

Finland
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Dry Eye Syndromes

United States
Alcon Research

Withdrawn

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis
Huons Co., Ltd.

Not yet recruiting

To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye Syndrome

Dry Eye Syndromes
Cairo University

Unknown

Evaluation of Deep Topical Fornix Nerve Block Versus Topical Anaesthesia Procedure

Local Anesthesia | Satisfaction

Saudi Arabia
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber

Conjunctivitis, Allergic

Canada
Aldeyra Therapeutics, Inc.

Completed

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Alcon Research

Completed

Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects

Dry Eye
Horus Pharma

Unknown

Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness

Dry Eye
Rigel Pharmaceuticals

Completed

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca (DROPS)

Keratoconjunctivitis Sicca

United States
Aldeyra Therapeutics, Inc.

Completed

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Medical University of Vienna

Completed

A Pilot Study Investigating the Impact of Different IOL Designs on Subjective 2D and 3D Image Quality

Visual Acuity | Lenses | Intraocular Sensitivity

Austria
pH Pharma

Completed

PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects

Healthy Volunteer

Korea, Republic of
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
Alcon Research

Completed

Acute Comfort of Lubricant Eye Drop FID 111421

Dry Eye
Rigel Pharmaceuticals

Completed

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Alcon Research

Completed

An Evaluation of the Daytime Use of an Investigational Lubricant Eye Drop

Dry Eye
Alcon Research

Completed

An Evaluation of the Nighttime Retention of Effect of an Investigational Lubricant Eye Drop (FID 115958D)

Dry Eye
pH Pharma

Completed

Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

Normal Tension Glaucoma

Korea, Republic of
Alcon Research

Completed

Clinical Outcomes Following Treatment With SYSTANE® BALANCE

Dry Eye
New York Presbyterian Brooklyn Methodist Hospital

Unknown

Treatment of Corneal Abrasions With Topical Tetracaine

Corneal Abrasion

United States
Johnson & Johnson Vision Care, Inc.

Completed

Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients

Dry Eye

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye | Dry Eye Syndromes

United States
Alcon Research

Terminated

Clinical Evaluation of Systane® Balance in Dry Eye Subjects

Dry Eye
Ospedale San Raffaele
Dompé Farmaceutici S.p.A

Completed

Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema (NEMO)

Retinitis Pigmentosa | Cystoid Macular Edema

Italy
Alcon Research

Completed

Residence Time Evaluation of Systane Ultra Lubricant Eye Drops vs. Hialid and Saline

Dry Eye Syndrome
Bausch & Lomb Incorporated
Synteract, Inc.

Completed

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Keratoconjunctivitis Sicca

United States
Aerie Pharmaceuticals

Completed

Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

Glaucoma

United States
Chang Gung Memorial Hospital

Unknown

Effect of Preservative-free Low-dose Hyaluronic Acid-containing Salt Solution on Dry Eye Disease

Dry Eye

Taiwan
Aldeyra Therapeutics, Inc.

Completed

A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Syndrome

United States
IVIEW Therapeutics Inc.

Not yet recruiting

IVW-1001 Phase 1/2 in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Allergan

Completed

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

Dry Eye Syndromes

United States
University of California, Berkeley
Alcon Research

Completed

Artificial Tears, Tear Lipids and Tear Film Dynamics (AlconAT)

Dry Eye

United States
University Hospital of Patras

Completed

Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections

Pain

Greece
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Aston University
TearLab Corporation

Completed

Tear Osmolarity Clinical Utility in Dry Eye Disease

Dry Eye

United Kingdom
M.D. Anderson Cancer Center
Allergan

Withdrawn

Topical Cyclosporine vs. Placebo for Epiphora Associated With Docetaxel

Epiphora
Alcon Research

Completed

Acute Comfort and Blur Profile of a Lubricant Eye Drop Versus a Marketed Lubricant Eye Gel

Dry Eye
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Cornea Consultants Of Nashville
Bausch & Lomb Incorporated; SCRI Development Innovations, LLC

Terminated

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (Eye02)

Corneal Ulcers

United States
University of Miami

Withdrawn

Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma (TOPIAC)

Hemodynamic Instability

3

Subscribe